Dr. Lipson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
401 N. Broadway
Baltimore, MD 21231Phone+1 410-955-8964Fax+1 410-955-8587- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011- Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Icahn School of Medicine at Mount SinaiClass of 2005
Certifications & Licensure
FL State Medical License 2022 - Present
MD State Medical License 2008 - 2024
DC State Medical License 2012 - 2024
VA State Medical License 2021 - 2024
PA State Medical License 2020 - 2024
DE State Medical License 2022 - 2023- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Start of enrollment: 2018 Nov 27
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Start of enrollment: 2019 Nov 08
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Start of enrollment: 2024 Aug 11
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsNivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason J Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwa...> ;Journal of Clinical Oncology. 2024 Mar 20
- Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.Shuming Chen, Tracee L McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C Cappelli, Livia A Casciola-Rosen, Isaac R Morales, Preethi Sankaran, Alan E Be...> ;Journal of Translational Medicine. 2024 Mar 5
- Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade.Deutsch, J., Lai, J., Will, E., Engle, L., Xu, H., Ogurtsova, A., Madan, V., Chong, J., Wang, D., Green, B., Nguyen, P., Schollenberger, M., Schenk, K., Soni, A., Lips...> ;Journal for Immunotherapy of Cancer. 2023 Dec 14
- Join now to see all
Journal Articles
- From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World SettingKaren B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
- Nodular Regenerative Hyperplasia Associated with Immune Checkpoint BlockadeEvan J Lipson, Michael I Brener, Jaclyn LoPiccolo, James P Hamilton, Hepatology
Press Mentions
Toxic Trade-OffsMarch 16th, 2023- Evan Lipson, MD, on Nivolumab plus Relatlimab for Advanced MelanomaJuly 14th, 2022
- ASCO: Nivolumab, Relatlimab Combo Slows Advanced MelanomaMay 30th, 2021
- Join now to see all
Hospital Affiliations
Johns Hopkins HospitalBaltimore, Maryland
Sibley Memorial HospitalWashington, District of Columbia
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/evan-lipson
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
